Vaxcyte, Inc.

NASDAQ:PCVX

Biotechnology

Healthcare
$58.52 +3.83%

+$1.94 today

Market cap
$9.26B
Beta
1.24
P/E (TTM)
-7.8
EPS (TTM)
-$6.78
52W Low $29.08High $65.00

Volume 1.13M

Average 1.44M

PCVX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Vaxcyte, Inc.NASDAQ: PCVX

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $267.85M rose 37.9% year over year, behind the +74.2% change in trailing-twelve-month research & development. Sequentially, it fell 14.4% from the prior quarter. Over 3 fiscal years it compounded at +67.4% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +37.9% toward the trailing-twelve-month pace of +74.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$267.85M-14.4% QoQ
Last fiscal yearDec 2025
$794.31M+66.6% YoY
LTMJun 2026
$1.03B+74.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.9%——
1 year+66.6%——
3-year CAGR+67.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
794.31M USD
Year-over-year change
+66.6%
4-year CAGR
+78.4%

Research & Development vs competitors

How PCVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +74.2% is the highest of 9, against a peer median of -1.9%.
  • Over three fiscal years its annual growth of +67.4% compares with a peer median of -4.4%.
PCVX Competitors
Research & Development for PCVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$11.05B USD+7.0%-3.0%17.3%
GSKGSK plcLTM Jun 2026£9.2B GBP+31.8%+11.1%27.7%
MRNAModerna, Inc.LTM Sep 2026$2.66B USD-23.6%-1.7%105.3%
PCVXVaxcyte, Inc.LTM Jun 2026$1.03B USD+74.2%+67.4%—
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M USD-15.0%-3.0%681.3%
NVAXNovavax, Inc.LTM Mar 2026$345.36M USD-10.9%-35.2%57.9%
IBRXImmunityBio, Inc.LTM Sep 2026$252.23M USD+33.2%-5.7%138.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$98.25M USD-44.3%-8.8%216.6%
VALNValneva SELTM Mar 2026€85.57M EUR+12.6%-6.7%54.7%
Peer median (excluding PCVX) —-1.9%-4.4%81.6%

Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development78.41M169.45M332.34M476.64M794.31M
Selling, General & Admin25.26M39.81M60.7M92.9M129.37M
Operating Expenses103.67M232.26M468.04M569.55M923.68M
Depreciation & Amortization3.46M9.45M10.17M15.85M24.86M
EBITDA(96.61M)(214.03M)(392.1M)(448.08M)(741.77M)
EBITDA Margin—————
Operating Income(103.67M)(232.26M)(468.04M)(569.55M)(923.68M)
Operating Margin—————
Interest Income344K8.36M62.91M109.99M119.72M
Interest Expense7K2K000
Other Income / Expenses3.59M8.77M65.78M105.62M157.05M
Income Before Tax(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Net Margin—————
EPS (Basic)(1.93)(3.44)(4.14)(3.80)(5.63)
EPS (Diluted)(1.93)(3.44)(4.14)(3.80)(5.63)
Weighted Avg Shares51.92M64.88M97.16M122M136.09M
Weighted Avg Shares (Diluted)51.92M64.88M97.16M122M136.09M

Vaxcyte, Inc.

NASDAQ:PCVX

Intrinsic Alpha fair value

Locked

Current Price

$58.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.